Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Seeking Alpha site, today: Nano cap Aethlon Medical (AEMD +33.3%) spikes on modestly higher volume in apparent response to an upcoming segment of 60 Minutes (Sunday, Jan. 7) about the same degenerative brain disease in soldiers returning from combat as former football players.
The disorder, chronic traumatic encephalopathy (CTE), was found in 110 of 111 brains of deceased NFL players in a study conducted at Boston University.
It appears that soldiers endure similar brain trauma from bomb blasts in combat.
The company is the majority stockholder in Exosome Sciences which discovered a biomarker called TauSome that can potentially be used to detect CTE in living persons.
seekingalpha.com/news/3321235-aethlon-medical-33-percent-ahead-60-minutes-report-cte-combat-veterans
Seeking Alpha site, today: Nano cap Aethlon Medical (AEMD +33.3%) spikes on modestly higher volume in apparent response to an upcoming segment of 60 Minutes (Sunday, Jan. 7) about the same degenerative brain disease in soldiers returning from combat as former football players.
The disorder, chronic traumatic encephalopathy (CTE), was found in 110 of 111 brains of deceased NFL players in a study conducted at Boston University.
It appears that soldiers endure similar brain trauma from bomb blasts in combat.
The company is the majority stockholder in Exosome Sciences which discovered a biomarker called TauSome that can potentially be used to detect CTE in living persons.
seekingalpha.com/news/3321235-aethlon-medical-33-percent-ahead-60-minutes-report-cte-combat-veterans
E*TRADE also no shares showing. Fidelity showing shares with Buy/Sell working fine.
AEMD RS: a positive article published tonight
http://www.microcapdaily.com/an-eye-on-bigger-things-aethlon-medical-inc-otcmktsaemd/110160/
An Eye on Bigger Things: Aethlon Medical, Inc. (OTCMKTS:AEMD) 0
BY DANIEL MCCARTHY ON APRIL 8, 2015 MICRO CAP INSIDER, SMALL CAPS
Aethlon Medical, Inc. (OTCMKTS:AEMD) is seeing red after the Company released an 8k on Tuesday announcing a 1-for-50 reverse stock split. Management wants to seek listing on a higher exchange where they can attract institutional investors.
Thus far the market does not like this news at all, we will see if this changes; everyone seems to think that RS is bad and usually results in lower PPS as the result of panic selling etc., but if we really examine the issue we come to an entirely different conclusion. Yes in almost all cases when a non-revenue, sub penny co with a history of dilution does another RS it almost always ends in more downside. And this is the only logical outcome; if management is doing a RS so they can continue to further dilute shareholders why would any shareholder not sell.
At the other end of the spectrum when an established Company such as AEMD with real products does a RS so they can up list and expose their Company to a higher bread of investor it almost always results in significant moves to the upside; let’s look at some recent established Company RS examples; CTSO did a 25 for 1 RS on December 1, 2014 the stock opened after the RS at just over $4 a share and quickly ran to over $12 in 3 weeks.
Another established Company RS recently was SIAF which did a 9.9 for 1 RS on December 16, 2014 the stock opened after the RS at just over $6 a share and was trading over $9 by the next day. Even if we look back farther and take MSLP which did a 850 for 1 RS on November 26, 2012 opened after the RS at just over $4 and was trading over $12 a share within 6 months.
So I reject the general consensus that is going around that RS will result in a dropping PPS; on the contrary RS could be the catalyst that takes this one to the next level.
Aethlon Medical, Inc. (OTCMKTS:AEMD) is a Medical Device Company focused on creating innovative devices that address unmet medical needs in cancer, infectious disease and other life-threatening conditions.
The Aethlon Adaptive Dialysis-Like Affinity Platform Technology System (ADAPT™) is a medical device platform that converges single or multiple affinity drug agents with advanced plasma membrane technology to create therapeutic filtration devices that selectively remove harmful particles from the entire circulatory system without loss of essential blood components.
Recently AEMD successfully used their bio-filtration device, the Aethlon Hemopurifier® to treat a critically-ill Ebola-infected patient in Frankfurt, Germany. The patient was a Ugandan Doctor, who was infected with Ebola in Sierra Leone where he was treating Ebola patients. At the time of treatment, which occurred at Frankfurt University Hospital, the patient was unconscious and suffering from multiple organ failure.
Recent date suggests a million Ebola viruses were captured within the Aethlon Hemopurifier® during treatment, a number verified by a post-treatment elution protocol. The patient is no longer infected with Ebola virus and is expected to make a full recovery.
The Hemopurifier® is a first-in-class bio-filtration device designed for the single-use removal of viruses and shed glycoproteins from the circulatory system of infected individuals. The device targets antiviral drug resistance and serves as a first-line countermeasure against Ebola and other viruses that are not addressed with proven drug therapies.
We have a Monster Pick Coming. Subscribe Right Now!
Currently trading at an $82 million market valuation AEMD does have $2.7 million in the treasury, manageable debt and small revenues. AEMD is an exciting opportunity developing in small caps; the Company recently successfully treated a critically-ill Ebola-infected patient with the Aethlon Hemopurifier® and This was followed by the FDA approving a clinical protocol to treat Ebola-infected individuals in the U.S. with the Aethlon Hemopurifier®.
We will be updating on AEMD on a daily basis so make sure you are subscribed to microcapdaily.com so you know what is going on with AEMD.
FDA Approved new IDE Aethlon Ebola Clinical Study
8-K filed this morning
On December 23, 2014, Aethlon Medical, Inc. (“Registrant” or the “Company”) received notification from the U.S. Food and Drug Administration (the “FDA”) that the FDA had approved the Company’s Investigational Device Exemption (“IDE”) supplement proposing use of the Aethlon Hemopurifier® to treat subjects infected with the Ebola virus. The Company previously reported, in a Current Report on Form 8-K filed on June 25, 2013, the FDA’s approval of an IDE permitting the Company to initiate human feasibility studies of the Hemopurifier in the U.S. for the purpose of treating persons infected with the Hepatitis-C virus. The Company filed the IDE supplement request in order to establish a uniform protocol to clinically investigate the use of the Hemopurifier as a treatment for Ebola-infected individuals in the U.S.
The FDA has limited the investigational Ebola study to 10 U.S. clinical sites, and up to 20 U.S. subjects may be enrolled to receive the treatment protocol. The use of the Hemopurifier in the proposed Ebola treatment protocol will be a deviation from the Hepatitis-C virus protocol being used in the Company’s clinical trials. The Company must clearly distinguish data collected in the supplement Ebola protocol study from data derived from the Company’s Hepatitis-C virus trials. The Company may not combine data from the two studies.
The Company must also comply with specified patient protection procedures established by the applicable institution including its institutional review board prior to treating a patient under the supplement protocol and must report any unanticipated adverse events resulting from the supplement protocol to the FDA within 10 working days of the use of the device.
There can be no assurance that any Ebola-infected patients will be treated. Even if the Ebola treatment protocol is established for the Hemopurifier, and patients are treated, the results of such treatments may not demonstrate the safety and efficacy of the device, may be equivocal or may otherwise not be sufficient to obtain approval of the Hemopurifier for any uses associated with Ebola, or for approval to conduct expanded studies or clinical trials. In addition, the FDA’s approval of the IDE supplement does not in any way ensure FDA clearance or approval of the Hemopurifier device for any purpose.
AEMD's Rod Kenley & Dr Ronco recent video
thanks ace1mc for finding this
5 minute youtube "The Role of Extracorporeal treatments in patients with Ebola Virsu Infection. Rod Kenley from Aethlon Medical and Prof Claudio Ronco discuss the use of the Hemopurifier: a new device design to reduce viral particle concentration in blood."
no new info, but good to see the promo efforts being made
Agreed. and having dramatically positive HCV outcomes, based upon solid clinical data out of Medicity -- at the time of the IDE HCV trails starting within a couple weeks creates a great context to reinforce the significance of the HP as a real breakthrough!
Thanks for your response Bill. After all these years, it is very encouraging to know that the work in India can still provide further support for making the case for the HP in treating HCV.
BBarry
Meanwhile AEMD's HCV Studies in spotlight very soon!
Interesting to see in yesterday's presentation, Slide 26 on near-term clinical goals, we will see presumably some new data from the Medanta Medicity HCV study in India. Surely enough time has gone by since the earlier, very positive, reported clinical results, that we should see some data on longer-term outcomes...as stated on slide 26 "by month end"
This report will coincide with the actual start of the FDA approved IDE trials on HCV patients - For the first clinical treatments in the US. Time for gaining real traction on the HCV front, as well!
http://wsw.com/webcast/seethru9/aemd/index.aspx
Two Gems found by Klait today! While we await tomorrow's anticipated update, I put your "A case in Frankfurt looks hopeful" as a sticky to top of list. Thanks Klait.
IHUB ADMIN has been contacted for assistance, re posters who may violate terms of use.
I agree Bill that there are many reasons we want to pay attention to CTSO. Although on Friday several frequent posters on the AEMD IHUB board, stated concerns about not wanting to see Paulness pumping CTSO on the AEMD board, so I think it is concern we want to pay attention to, in case someone overdoes it with CTSO posts. Meanwhile, information about CTSO that is relevent to AEMD's interests certainly has value to us.
Regarding my claim that Paulness engages in bashing AEMD, I may be wrong, but I see it as a subtle form of bashing AEMD, for someone who stated on the CTSO board that he no longer owns AEMD and only posts on the AEMD board infrequently, to make multiple posts while AEMD is in the midst of a significant intra-day price/volume surge with the essence of those posts trying to highlight why CTSO is better than AEMD. Certainly both of these companies have significant strengths and great potential that there is no need for someone to talk one down to try to make their case for the other one.
Although Paulness is an infrequent poster here, on other occasions, his posts have been constructive… so, if I am wrong about him bashing, I’ll be happy to drop the concern.
BBarry
Paulness, on Friday many us noticed your pumping of CTSO as well as some bashing of AEMD. Friday was not the first time you have done this on the AEMD board. Other times in the past as well, I have noticed your clever and sometimes subtle bashing of AEMD, in the form of trying to plant seeds of doubt about AEMD. Please stop posting about other stocks on this board.
Right now, there is no one banned from posting to this stock board. That will change if we have repeated patterns of someone bashing, or promoting unrelated stocks or topics here.
Please let me know, in a public post or private message, if you have any questions or concerns about this.
BBarry
bkbbk5/Bill - I'm sure some of us recall your many excellent, insightful and well researched posts, in the yahoo AEMD group, in prior years. Wonderful that you are with us here. Welcome.
BBarry
here is link to Facebook for JJ's blog entry.
https://www.facebook.com/aethlonmedical?rf=109537212399571
great idea to try to gain visibility on these social media sites.
a somewhat rare Monday Press Release today.
and a statement of "Additional study details will be presented at the Exosomes & Single Cell Analysis Summit to be held on September 18th and 19th, 2014"
Since in the past few years, I think JJ almost always does the PRs on Tue, Wed or Thursdays, with a majority being Tuesdays.... my wishful thinking hopes this Monday PR means we could see some other positive news announced in the next few days.
Philife . I noticed your departure as one of the moderators. Thanks for your many excellent high-quality contributions to this group. I hope you will continue to post. BBarry
HTT. is your post a direct quote from Amber Brantly (Dr. Brantly’s wife)? If so, can you provide a link or source?
thanks
BBarry
one way it could happen, Craig, is that at some point, whether it is with this current Ebola need, or some other application, some one of the MD's affiliated with Aethlon, either on thier Board, or some Advisary group, could take some steps to bring the right resources to play, perhaps outside of the US/FDA controls, and in one of these dramatic needs they could initiate some clinical treatments that could add another demonstration of the results possible with the HP.
Beyond the constraint of the very limited employee time that Aethlon can apply on any project, some one of these academic or clinical affiliates could be motivated to take the initiative.
This may be wishful thinking... but the more MDs and researchers who become associated with and/or personnaly invested in Aethlon, the possibility of what I suggest could increase.
These potential Ebola ~ Aethlon links may help stop the current slide downward!
Anyone that does a search on Aethlon Ebola may become motivated to learn more.
http://www.marketwatch.com/story/aethlon-medical-announces-online-access-to-infectious-disease-and-cancer-therapy-presentation-2014-06-25
panic selling with lemmings following it down, is my guess. and some buyers getting bargain prices.
Encouraging to see today's news. we need to see more of these peer-reviewed journal confirmations (along with news re real revenue).
But a key positive in the 8K was closure on this litigation. That should help in removing that dark cloud as we, finally, move forward with the clinical trials.
also from that Zack's report (thanks Craig), is a helpful summary of what has been previously reported on the FDA approved IDE/HCV clinical trials: That full 11 page report is worth reading, but below, I've pasted in just their summary of the awaited 10 patient clinical trial.
pasted in below, from Brian Marckx's Zacks report.
http://scr.zacks.com/files/doc_coverage/Med-Tech%20-%20Brian%20Marckx/AEMD/February%2012%202014_AEMD_Marckx.pdf
Hemopurifier FDA Approved Human StudyAfter a years-long quest, Aethlon Medical (AEMD) cleared what we view as a major milestone, announcing in late June that they received IDE approval to initiate a human feasibility study with Hemopurifier. Whether FDA would approve an IDE was an ongoing question in our mind and, given that such an approval would be required as a first step towards potential U.S. commercialization (where we believe the bulk of potential opportunity lies) of the device, was something that could have been highly detrimental to AEMD had FDA denied the IDE request.
As a reminder, in early January 2013 AEMD announced that they submitted an IDE to the FDA seeking approval to commence a 10-patient safety and effectiveness feasibility study of Hemopurifier. Included in the submission was data from the recent and ongoing studies at hospitals in India as well as HCV capture data, the latter which that the FDA had requested at a pre-IDE meeting in 2011. Then in late-March, following response from FDA which included comments and study design considerations, AEMD resubmitted the IDE. FDA subsequently communicated that they were withholding clearance of the IDE until AEMD addressed the agency's safety concern, namely that the company detail their training and monitoring procedures for heparinization - the anticoagulant used during dialysis and with the Hemopurifier. AEMD noted in early May that they were gathering the requested information and expected to have it submitted to FDA in the coming week (i.e. - by mid-May). Given this recent news of the approved IDE, FDA's safety concerns have clearly been satisfied.
The feasibility study will enroll 10 end stage renal disease patients infected with HCV to demonstrate safety of Hemopurifier therapy. The patients, which must not have received any HCV drug therapy for at least the preceding 30 days, will receive three treatments of standard dialysis in the first week (i.e. - control phase), followed by a total of six dialysis treatments using Hemopurifier over the next two weeks. The rate of adverse events during the control and Hemopurifier treatments will be compared. Viral load changes will also be measured in order to provide an indication of efficacy. AEMD also notes that they may also collect HCV capture data (another efficacy metric with positive results in trials in India and which FDA had previously indicated interest in). AEMD had previously announced that the study was expected to be conducted by the Renal Research Institute, a partnership between Fresenius Medical Care (FMS), a leader in dialysis products and services, and Beth Israel Medical Center in NYC.
AEMD is now in the process of preparing for the study. Assuming positive results, the expectation is this will lead to larger U.S. studies to support an eventual FDA approval filing. And while we do not expect U.S. commercialization to be a near-term event, IDE approval to conduct human studies is a huge positive, meaningful hurdle that's now cleared and significantly increases the likelihood of initiation of larger studies to support an eventual FDA filing.
In mid-October AEMD announced that they expect to begin manufacturing the Hemopurifier in the coming weeks which will be used in the FDA approved study and further noted that they now have a processing technique that optimizes the ability of the affinity agent in the device to bind to blood borne viruses and pathogens. AEMD's prior timeline was for manufacturing to be completed by the end of calendar 2013 with patient treatment to begin in Q1 2014. These timelines have likely been pushed back however.
Very helpful highlights from the 10-Q, ANESRI. Thanks for posting them.
Impressive CTSO move on 11X recent volume. the seekingalpha article no doubt had a postive impact. interesting. thanks
Would be nice to get news & some specifics on the start of the already approved IDE Clinical feasiblity study of HCV patients. It was just a year ago, Jan. 3, 2013, that Aethlon, in announcing their IDE proposal to the FDA, that they stated that "The study would be conducted by the Renal Research Institute (RRI), which was established in 1997 as a partnership between Fresenius Medical Care (FMC) and Beth Israel Medical Center, New York City." http://aethlonmedical.investorroom.com/2013-01-03-Aethlon-Medical-Discloses-Submission-of-Hepatitis-C-Virus-HCV-IDE-to-FDA
The news of the FDA approval of this clinical study came out June 25, 2013 http://aethlonmedical.investorroom.com/2013-06-25-Aethlon-Medical-Announces-FDA-Approval-of-IDE-to-Treat-Hepatitis-C-HCV-Patients
remains to be seen who the final partners are, but is sure seems like we are due some news on this.
Today's price/volume will surely attract some notice. Broader markets down and AEMD up, closes at HOD on better than 4X ave volume.
Very nice timing on this article today. Thanks philife!
since about 2pm large bid size (at or above .14/share) sustained at 689,000+ shares, then 670,000+ shares thru the past 100+ minutes. Assuming those are real bids, I don't think we've seen that level of bid interest in quite a while.
If investors are to agree with you, about the cash added by sales of ESI shares, it will take more than just one or two trading days for that to result in bigger sp gains. Hopefully a low volume thanksgiving week, won't be a negative.
Given that AEMD & ESI's cash position has improved dramatically with these two recent 8Ks, as well as the substantial cash gained after close of Qtr2 as reported in the recent 10Q, the stage is more than set for the coming months.
trading volume has been quite low, 8 out of past 9 trading days.
Not sure what you mean my "unload so many shares". The downtrend of the past 8 days, has been low volume. Frustrating, yes. But low volume.
perhaps the other co-host will be an industry heavyweight and so
JJ's intention is to save that news, until the day of the "grand opening" to get some better news impact on the 12th?
Fidelity is now showing lowest ASK is 9000shares @0.18 and
highest bid is 10,000 shares @0.1375 and zero volume for the day.
that has been the display for at least the past 30 minutes.
Thanks for posting that video interview Paulness. Although it was some of JJ's basic presentation script, it could be a helpful intro for new investors.
THanks Philife for your attention to these details. very helpful.
CTSO did not mention Aethlon working with Battelle, most probably because CTSO (like AEMD) is a small company and so CTSO's PR wants to just showcase that CTSO is in partnership with Battelle and NxStage.
Seems logical that CTSO did not want to highlight any other filtration device company, other than themselves.
I’ll add my thanks StlCardsRgr8 for your recent post about the concerns about Aethlon’s cash situation. Certainly I was among those encouraged by the recent SA article and the patent news. But, I appreciate your reminder that significant cash-flow challenges remain. For a long time now, your posts, StlCardsRgr8, have often included facts and a thoroughness that many of us deeply appreciate.
Hopefully this board can maintain some pragmatic realism, balance, and an ability to hear legitimate cautions even if they run counter to the “see you in Vegas” enthusiasm.
the recent SA article, and the fact that some Seeking Alpha subscribers pay for 24 hour early access to their articles, most probably explains the spike in volume and share price that began Monday morning.
Yes, this Seeking Alpha article & visibility seems significant, especially since it is backed up by the recent FDA news, the ongoing DARPA work and the limited but positive data out of the black box of the India Medanta Medicity work.
in last 30 minutes, major volume trading, most trades at or near the ask. Volume highest we've seen in several weeks.
could be interesting to see if intraday gains hold.
Drop doesn’t seem that surprising given the opportunity for short-term profits on some of the large blocks recently purchased in the 7,8, & 9 cent range. We may see this profit-taking followed by a new base in the 11s or 12s. I say that since the FDA approval of the IDE should stand out as a real milestone, building on the last couple years of DARPA news.
Although we’ve all said this before when waiting for AEMD news, it seems that it should not take very long to name the partners and institutions involved in the IDE study! That announcement, plus (wishful thinking?) some signs of at least some revenue from India in the imminent(unless delayed) 10-Q, or some additional patient data out of India, would certainly help.
Volatility is not surprising, but perhaps the next renewal of the DARPA contract will bring enough momentum to sustain an uptrend?